Micro-x Ltd. · ASX:MX1

Micro-x — Investor Presentation (December 2024)

22 slides from Micro-x's investor presentation, Dec 10, 2024

  1. Slide 1: Investor Presentation

    For personal use only INVESTOR PRESENTATION Kingsley Hall C h i e f E x e c u t iv e O f f i c e r December 2024 Micro-X Investor Presentation I 1

  2. Slide 2: Important Notice

    IMPORTANT NOTICE S C O P E & L I M I T A T I O N S This Presentation has been prepared by Micro-X Limited (Micro-X or the Company) (ASX.MX1). The Presentation is a summary only and does not contain all the information about the For personal use only Company’s assets and liabilities, financial positi

  3. Slide 3: Creating Revolutionary X-Ray Imaging to Better Lives

    For personal use only CREATING REVOLUTIONARY X-RAY IMAGING TO BETTER LIVES Curious I Collaborative I Determine d Micro-X Investor Presentation I 3

  4. Slide 4: Overview

    OVERVIEW Building on commercial momentum achieved during the past 18 months For personal use only 1 Focus on execution – commercial revenue – funded development – strategic partners 2 Up to A$25m Contract for Full Body CT scanner – US Government Agency ‘ARPA-H’ – Non dilutive funding to develop prot

  5. Slide 5: World First Imaging Technology

    WORLD FIRST IMAGING TECHNOLOGY For personal use only Micro-X proprietary CNT Micro-X has created a world first technology technology Lighter platform that delivers transformative - Cold cathode emitter made of imaging solutions millions of nanotubes emits digitally controlled electrons Cold cathode

  6. Slide 6: Four Innovative Applications

    FOUR INNOVATIVE APPLICATIONS Smaller and smarter X-ray and CT enabled through Micro-X’s patented technology platform For personal use only MOBILE DIGITAL ARGUS X-RAY CAMERA CHECKPOINTS & MEDICAL CT RADIOLOGY BAGGAGE CT SCANNER Lightweight and ultra-mobile x-ray World first high-definition bomb imagi

  7. Slide 7: New Full Body CT

    For personal use only NEW FULL BODY CT Extending World leading Head CT technology

  8. Slide 8: World First - 3D Head CT Images

    WORLD FIRST - 3D HEAD CT IMAGES $0.5m milestone achieved - preparing hospital systems for human clinical trials in early 2025 For personal use only Saving lives with stroke diagnosis in any ambulance → Mobile – 70kg unit suitable for all road and air ambulances → Accurate – 8 second scan for 3D imag

  9. Slide 9: Current CT Imaging Technology

    CURRENT CT IMAGING TECHNOLOGY CT Imaging is a large and growing area of the diagnostic imaging market For personal use only CT scanning is a common diagnostic tool → Diagnostic imaging using a combination of X-rays and computer technology → Detailed images of any part of the body - bones, muscles, f

  10. Slide 10: Micro-X Full Body CT Solution

    MICRO-X FULL BODY CT SOLUTION Extension of current Micro-X NEX technology – to bring CT scanning to the patient For personal use only Micro-X Investor Presentation I 10

  11. Slide 11: Up to $25M Non-Dilutive Funding Contract

    UP TO $25M NON-DILUTIVE FUNDING CONTRACT* Fully funds the development of Micro-X proprietary, portable, Full Body CT scanner For personal use only Micro-X Inc. has signed an up to $25m development funding contract → Up to A$25M across 5-year programme - Lightweight, portable and ruggedised Full Body

  12. Slide 12: Advantages of Micro-X CT

    ADVANTAGES OF MICRO-X CT For personal use only SIMPLER SYSTEM COST EFFECTIVE No rotating slip ring More cost effective system No oil cooling to build and install Simple CNT tubes Cheaper to maintain & operate SMALL & PORTABLE PATIENT BENEFITS Smaller & lighter system is Lower X-ray dosage portable a

  13. Slide 13: Driving Commercial Success

    For personal use only DRIVING COMMERCIAL SUCCESS B u i l d i n g a b u s i n e s s n o t j u s t a t e c h n o l o g y

  14. Slide 14: Our Priorities

    OUR PRIORITIES Executing on identified priorities to drive commercialisation For personal use only 1 Build Micro-X Rover sales – major hospital evaluation underway 2 Commence Head CT human trials and begin ARPA-H prototype design work 3 Checkpoints & Baggage scanner work to project plans – DHS funde

  15. Slide 15: Rover - Targeting Larger Sales

    ROVER – TARGETING LARGER SALES Streamlined Mobile DR team delivering record revenues For personal use only Sales up 70% in FY24 to $6.4M → Higher value orders and stronger price points – delivered improved margins Trial underway with a major US hospital & buying group → Second stage evaluation under

  16. Slide 16: Checkpoints - Building Momentum with DHS

    CHECKPOINTS – BUILDING MOMENTUM WITH DHS Achieving key deliverables under our two Department of Homeland Security contracts For personal use only Baggage Scanner prototypes – supporting TSA testing → Initial prototype installed at DHS test laboratory in May 2024 → Second unit commissioned and comple

  17. Slide 17: Argus - Updated Product Strategy

    ARGUS – UPDATED PRODUCT STRATEGY Combining backscatter with transmission for a compelling value proposition For personal use only Customer demonstrations & feedback → Law enforcement, security and military → Challenge to break current operating practices using transmission images Redefined Argus kit

  18. Slide 18: Progressing New Strategic Partnerships

    PROGRESSING NEW STRATEGIC PARTNERSHIPS Realising value from our development work with the right strategic partners For personal use only Varex – World’s largest OEM manufacturer → Two-year technology transfer completed - $7.5M received → Proof of concept – validates transferability of technology → O

  19. Slide 19: Experienced Leadership

    EXPERIENCED LEADERSHIP Commercially focused to accelerate growth For personal use only Ilona Meyer, Non-Exec Patrick O'Brien , Non-Exec Kingsley Hall – Chief Executive David Knox – Non-Exec Chair General Counsel Nuix, former Boehringer Former Senior Exec. Macquarie 25+ years exp in senior operationa

  20. Slide 20: Corporate & Financials

    CORPORATE & FINANCIALS For personal use only FINANCIALS & SHAREHOLDERS SHARE CAPITAL (9 December 2024) $15.2m FY24 Revenue ~A$3.0m (30 Sept 2024) Cash + $6.4M R&D (Dec 2024) Share price $0.091 per share A$15.2m (FY2024) Revenue ($6.4m product revenue ↑70%) Total shares on issue 581.6 million $6.4m R

  21. Slide 21: Outlook for FY25

    OUTLOOK FOR FY25 Key near-term operational objectives Commercial products Products In Development Corporate & Financial For personal use only Argus Checkpoints Corporate > Commercial sales in security & defence > Deliver prototypes to demonstrate capability > Build and manage resources → Demonstrate

  22. Slide 22: Wrap Up

    WRAP UP Five key take aways For personal use only 1 Up to $25m Contract to develop Full Body CT scanner – leveraging Micro-X CNT advances major product and patient benefits for global CT scanning market 2 Head CT Scanner first successful images – imaging trials planned in CY2025 3 Commercialisation

Micro-X — Investor Presentation (December 2024) on 6ix